Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients.

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Meetings

Abstracts

2006 ASCO Annual Meeting

Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients.

Sub-category:

Non-Small Cell Lung Cancer

Category:

Lung Cancer

Meeting:

2006 ASCO Annual Meeting

Session Type and Session Title:

null, 2006 Best of ASCO Reston
null, 2006 Best of ASCO Beverly Hills
Oral Presentation, Lung Cancer I

Abstract No:

7008

Citation:

Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7008

Author(s):

J. P. Pignon, H. Tribodet, G. V. Scagliotti, J. Y. Douillard, F. A. Shepherd, R. J. Stephens, T. Le Chevalier, on behalf of the LACE Collaborative Group

Abstract:

Background: Several recent trials have shown a benefit of adjuvant cisplatin-based chemotherapy on overall survival (OS) in patients with non-small cell lung cancer (NSCLC). The aim of the Lung Adjuvant Cisplatin Evaluation (LACE) is to identify treatment options associated with a higher benefit, or groups of patients benefiting more from adjuvant chemotherapy. Methods: Individual patient data were collected and pooled from the five largest trials (ALPI, ANITA, BLT, IALT and JBR10) of cisplatin-based chemotherapy in completely resected patients, conducted after the NSCLC-meta-analysis (BMJ 1995, update ongoing). The interactions between patient subgroups or treatment types and chemotherapy effect on OS were analysed using hazard ratios (HR) and logrank tests stratified by trial. Results: With a median follow-up of 5.1 years, the overall HR of death was 0.89 (95% confidence interval [CI]: 0.82-0.96; p<0.005) corresponding to a 5-year absolute benefit of 4.2% with chemotherapy. There was no heterogeneity of chemotherapy effect among trials. The benefit varied with stage (test for trend, p=0.046) with the HR for stage I-A 1.41 [95% CI: 0.96-2.09], stage I-B 0.93 [0.78-1.10], stage II 0.83 [0.73-0.95] and stage III 0.83 [0.73-0.95]. The effect of chemotherapy did not vary significantly (test for interaction, p=0.10) with the associated drugs: vinorelbine (HR=0.80 [0.70-0.91]) etoposide/vinca-alcaloide (0.93 [0.80-1.07]) or other (0.98 [0.84-1.14]). There was no interaction between chemotherapy and sex, age, planned radiotherapy or planned total dose of cisplatin. Conclusions: Adjuvant cisplatin-based chemotherapy improves survival in patients with NSCLC. This benefit depends on stage and is greatest in patients with stages II and III. Our analysis suggests that platinum-based adjuvant chemotherapy may not benefit stage I-A patients. Results of disease-free survival will be presented at the meeting. Supported by PHRC and LNLCC

Associated Presentation(s):

1. Lung Cancer

Meeting: 2006 Best of ASCO Reston
Presenter: Alan Sandler, MD
Session: 2006 Best of ASCO Reston

2. Lung Cancer

Meeting: 2006 Best of ASCO Beverly Hills
Presenter: Philip Bonomi, MD
Session: 2006 Best of ASCO Beverly Hills

3. Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients.

Meeting: 2006 ASCO Annual Meeting
Presenter: Jean Pierre Pignon, MD, PhD
Session: Lung Cancer I (Oral Presentation)

Other Abstracts in this Sub-Category:

		1. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Meeting: 2006 ASCO Annual Meeting Abstract No: 7000 First Author: R. B. Natale Category: Lung Cancer - Non-Small Cell Lung Cancer
		2. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. Meeting: 2006 ASCO Annual Meeting Abstract No: 7001 First Author: M. A. Socinski Category: Lung Cancer - Non-Small Cell Lung Cancer
		3. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Meeting: 2006 ASCO Annual Meeting Abstract No: 7002 First Author: U. Gatzemeier Category: Lung Cancer - Non-Small Cell Lung Cancer
		More...

Abstracts by J. Pignon:

		1. Circulating endothelial cell (CEC) monitoring in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line bevacizumab (BEV)-based combination regimens: Results of the randomized phase II FNCLCC-ACCORD 13/0503 trial. Meeting: 2009 ASCO Annual Meeting Abstract No: 4071 First Author: F. Farace Category: Gastrointestinal (Colorectal) Cancer - Colorectal Cancer (including liver metastases)
		2. Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab. Meeting: 2009 ASCO Annual Meeting Abstract No: 4597 First Author: V. Boige Category: Gastrointestinal (Noncolorectal) Cancer - Other: Gastrointestinal (noncolorectal) Cancer
		3. Comparative use of perioperative chemotherapy (CT) in non-small cell lung cancer (NSCLC) between 2004 and 2007. Meeting: 2009 ASCO Annual Meeting Abstract No: 7564 First Author: B. Le Naour Category: Lung Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
		More...

Presentations by J. Pignon:

No items found.

Educational Book Manuscripts by J. Pignon:

No items found.